1388890-35-4

Basic information

• Product Name: (1r,4r)-N₁-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-N₄,N₄-dimethylcyclohexane-1,4-diamine
• CAS NO: 1388890-35-4
• Molecular Weight: 304.459
• Mol File: 1388890-35-4.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: (1r,4r)-N₁-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-N₄,N₄-dimethylcyclohexane-1,4-diamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1r,4r)-N₁-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-N₄,N₄-dimethylcyclohexane-1,4-diamine(1388890-35-4)
• EPA Substance Registry System: (1r,4r)-N₁-(5,6-dimethylthieno[2,3-d]pyrimidin-4-yl)-N₄,N₄-dimethylcyclohexane-1,4-diamine(1388890-35-4)

Safety Data

• Hazardous Substances Data: 1388890-35-4(Hazardous Substances Data)

Upstream product

• 1286275-84-0 tert-butyl ((1r,4r)-4-(dimethylamino)cyclohexyl)carbamate 
• 167298-52-4 (1r,4r)-N¹,N¹-dimethylcyclohexane-1,4-diamine 
• 108831-68-1 4-chloro-5,6-dimethyl-thieno[2,3-d]pyrimidine 

Relevant articles and documents

Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88L265P Diffuse Large B-Cell Lymphoma

Herein we report the optimization of a series of pyrrolopyrimidine inhibitors of interleukin-1 receptor associated kinase 4 (IRAK4) using X-ray crystal structures and structure based design to identify and optimize our scaffold. Compound 28 demonstrated a favorable physicochemical and kinase selectivity profile and was identified as a promising in vivo tool with which to explore the role of IRAK4 inhibition in the treatment of mutant MYD88L265P diffuse large B-cell lymphoma (DLBCL). Compound 28 was shown to be capable of demonstrating inhibition of NF-κB activation and growth of the ABC subtype of DLBCL cell lines in vitro at high concentrations but showed greater effects in combination with a BTK inhibitor at lower concentrations. In vivo, the combination of compound 28 and ibrutinib led to tumor regression in an ABC-DLBCL mouse model.